About 11% of people stopped taking the drug because of adverse events, compared to about 5% for the placebo
I led a phase II dose-ranging trial on liraglutide, and we found that over 20 weeks the 3.0 mg/d dose had an optimal profile of effectiveness and tolerability [14]
Tomas FM, Lemmey AB, Read LC, Ballard FJ
Research in earlier phases or small trials include evaluation of GLP-1s for cystic fibrosis-related diabetes, polycystic ovarian syndrome (PCOS), chronic obstructive pulmonary disease (COPD), Prader-Willi syndrome (PWS), asthma, substance or alcohol use disorder and as add-on to insulin for type 1 diabetes
There are two main types of heart failure, and over 50% of patients have heart failure with preserved ejection fraction (HFpEF), which is sometimes referred to as a stiff heart. With HFpEF, the heart still circulates blood normally, but the heart muscle is too stiff to relax and allow heart chambers to fill with blood between each beat